{"aiVersion":"1","content":{"id":"cmsi8tfhs0004juf6k25n0j7s","slug":"when-anti-inflammatory-heart-drugs-don-t-work-what-20260807","title":"When Anti‑Inflammatory Heart Drugs Don’t Work: What the Trials Tell Us","level":"HARD","publishedAt":"2026-08-07T01:05:16.523Z"},"topic":{"slug":"when-anti-inflammatory-heart-drugs-don-t-work-what-20260807","category":"health"},"article":{"paragraphs":["For decades researchers have debated whether inflammation is a cause of atherosclerosis or merely a marker of disease, and large clinical trials have produced evidence that is both illuminating and confounding. The 2017 CANTOS trial showed that canakinumab, an interleukin‑1β blocker, reduced major cardiovascular events among patients with prior myocardial infarction and elevated hsCRP, providing proof of principle that lowering specific inflammatory pathways can cut risk. Yet such success has not been uniform across agents or populations.","Subsequent studies have underscored this complexity. The CIRT trial found that low‑dose methotrexate, a broad anti‑inflammatory therapy, did not reduce cardiovascular events, and earlier pharmacologic approaches such as darapladib also failed in large outcome trials, suggesting that non-selective anti‑inflammatory strategies may not alter atherosclerosis. In July 2026 AstraZeneca and Ionis announced that eplontersen did not meet the primary endpoint in a Phase 3 trial for transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM), a distinct disease in which protein deposition, rather than classical atherosclerotic inflammation, drives pathology.","More targeted approaches remain under evaluation. Ziltivekimab, an antibody that inhibits the interleukin‑6 ligand, produced substantial reductions in hsCRP and thrombotic biomarkers in earlier studies, and the ZEUS cardiovascular outcomes trial is testing whether IL‑6 inhibition translates into fewer clinical events. If ZEUS and similar trials fail to show event reduction despite biomarker changes, investigators will need to reassess prevailing models, refine biomarker thresholds such as hsCRP and IL‑6, and identify which patients, if any, derive meaningful benefit. Consequently, while inflammation remains a plausible therapeutic target, current evidence demands precise hypotheses and careful trial design before clinicians alter practice."],"wordCount":259,"readTime":2},"vocabulary":[{"word":"transthyretin","example":"Transthyretin deposits cause ATTR-CM in some patients.","phonetic":"/trænzˈθaɪrəˌtɪn/","definition":"a blood protein that can misfold and form deposits in some heart diseases"},{"word":"amyloid","example":"Amyloid buildup can damage the heart muscle.","phonetic":"/ˈæmɪˌlɔɪd/","definition":"a protein that builds up abnormally in tissues and organs"},{"word":"interleukin-1β","example":"Canakinumab blocks interleukin-1β activity.","phonetic":"/ˌɪntərˈluːkɪn wʌn ˈbɛtə/","definition":"an inflammatory signaling molecule targeted by some therapies"},{"word":"hsCRP","example":"Doctors use hsCRP to gauge inflammation in heart patients.","phonetic":"/eɪtʃ ɛs siː ɑːr piː/","definition":"high-sensitivity C-reactive protein, a blood marker of inflammation"},{"word":"biomarker","example":"Lower biomarkers do not always mean fewer heart attacks.","phonetic":"/ˈbaɪoʊˌmɑːrkər/","definition":"a biological measurement used to indicate disease or response to treatment"}],"quiz":[{"answer":"transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM)","question":"For which disease did eplontersen fail to meet the primary endpoint in a Phase 3 trial?"},{"answer":"Ziltivekimab","question":"Which drug reduced hsCRP and thrombotic biomarkers in earlier studies?"},{"answer":"hsCRP and IL‑6","question":"Which biomarker thresholds are mentioned as needing refinement?"}],"discussion":[{"question":"Do you believe that blood tests for inflammation should be routine for people at risk of heart disease? Why?"},{"question":"Have you or someone you know taken medicines for inflammation? What was the result?"},{"question":"What worries you more: a drug that lowers a marker or a drug that lowers real events like heart attacks?"},{"question":"Would you accept a treatment that changes lab tests but has unclear effects on how you feel? Why or why not?"},{"question":"How would you explain to a friend why a promising drug can fail in a large trial?"}]}